88 Tobacco Dependence: Markers of High Nicotine Dependency & Combination Pharmacotherapy

Wednesday, August 15, 2012
Exhibit Hall (Kansas City Convention Center)
Dr. Brenda Douglass, DNP, FNP-C, MSN, CTTS , Endocrinology, Joslin Diabetes Center, Atlanticare Physicians Group (APG), Atlanticare, Egg Harbor Township, NJ

Learning Objectives

At the conclusion of this presentation attendees will be able to:

  1. Identify smoking prevalence and the impact on health and society. Describe indications for using combination, first-line medications in the treatment of tobacco dependence. Recognize high nicotine dependence markers and the impetus for using more intensive treatment modalities in 'real-world' populations, those with chronic health conditions. Identify various components of tobacco smoke and the importance of smoking cessation.

Cross Cutting Program Area(s): Increasing Diversity/Eliminating Disparities and Cessation

Audience:

The poster targets a variety of audiences interests extending to healthcare professionals, researchers, educators, and public health professionals identifying the manner in which application of the initiative had on improved health outcomes. Audiences will be able to derive applicable education for tobacco programs, identify markers of high nicotine dependence, and examine implications of tobacco use and interventions.

Key Points:

The purpose was to examine the efficacy of combination, first-line pharmacotherapy approved for quitting smoking in comparison to monotherapy in individuals demonstrating markers of high nicotine dependence by implementing evidence-based treatment modalities. Data was collected from English and Spanish speaking participants at a medical-home practice who had at least one chronic condition. Outcome data was obtained comparing implementation of an intervention with monotherapy to combination pharmacotherapy. Descriptive data was derived from four sources: a self-designed tobacco and health assessment form, demographic questionnaire, Fagerstrom Test for Nicotine Dependence, and an abstinence questionnaire. Abstinence rates in tobacco users (cigarette use) demonstrating markers of high nicotine dependence improved with combination pharmacotherapy.  Evidence-based practice guidelines supports use of combination pharmacotherapy and served as a catalyst for improved outcomes. 

Educational Experience:

A scholarly poster presentation will be the methodology employed to effectively display and communicate key points. 

Benefits:

The highly addictive nature of nicotine and low smoking cessation rates are compelling reasons for more intensive treatment modalities. Recognition of high nicotine dependence and the need for more aggressive interventions are pivotal in reducing morbidity and mortality, while ultimately reducing socioeconomic burdens.